[Neoton (exogenic phosphocreatinine) in combined therapy of chronic cardiac failure].

Abstract

To evaluate clinicohemodynamic effect of neoton (exogenic phosphocreatine) given in an intravenous course, the drug was added to standard scheme in 53 patients with chronic cardiac failure (6.0 g/day i.v. drip for 5 days or 3.0 g/day for 10 days). 20 control patients received standard therapy alone. A course neoton produced an increase in the ejection fraction, a reduction in end-diastolic and end-systolic left ventricular volumes. It is recommended to include neoton in the scheme of chronic cardiac failure treatment in the dose 3.0 g/day for 10 days.

• Authors: A O Nedoshivin, N B Perepech
• Journal: Klinicheskaia meditsina (Klin Med (Mosk)) Vol. 74 Issue 9 Pg. 45-8 ( 1996) ISSN: 0023-2149 [Print] Russia (Federation)
• Vernacular Title: Primenenie neotona (eksogennogo fosfokreatinina) v kompleksnoi terapii khronicheskoi serdechnoi nedostatochnosti.
• PMID: 9121090 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Cardiotonic Agents
• Diuretics
• Phosphocreatine

Topics

• Cardiotonic Agents (therapeutic use)
• Chronic Disease
• Diuretics (therapeutic use)
• Drug Administration Schedule
• Drug Therapy, Combination
• Heart Failure (drug therapy, physiopathology)
• Hemodynamics (drug effects)
• Humans
• Infusions, Intravenous
• Male
• Middle Aged
• Phosphocreatine (administration & dosage)
• Treatment Outcome